Indegene equipped a global research-driven pharmaceutical company with prelaunch market impact insights for its new second- and third-line colorectal cancer (CRC) drug. To pinpoint eligible patient groups and quantify those shifting from Best Supportive Care (BSC) to active treatments, Indegene's analytics software conducted sophisticated market analysis. It modeled patient journeys, calculated eligibility percentages, and forecasted uptake potential—delivering precise, data-backed insights that informed launch strategies, optimized targeting, maximized market penetration, and accelerated transformation of cancer patient lives through timely commercialization.

Join for free to read